HQH vs JPM
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
HQH presents a complex profile with a stable Piotroski F-Score of 5/9 and a significant valuation discount, trading well below its Graham Number ($26.72) and Intrinsic Value ($47.5). However, these value metrics are offset by severe fundamental deterioration, specifically a -48.70% YoY revenue decline and an unsustainable dividend payout ratio of 139.13%. While historical price performance is positive, the current technical trend is heavily bearish (10/100) and liquidity is tight with a current ratio of 0.77. The stock is a value trap candidate where low multiples are justified by declining growth and dividend risk.
JPM exhibits a concerning Piotroski F-Score of 2/9, indicating weak short-term fundamental health, and currently trades at a significant premium to both its Graham Number ($239.11) and Intrinsic Value ($140.07). While the company maintains a strong ROE of 16.13% and dominant market positioning, negative YoY earnings growth (-3.60%) and bearish insider activity from the CEO and CFO signal internal caution. The stock's current price of $313.68 suggests the market is pricing in a growth premium that is not currently supported by the deterministic health or value metrics.
Compare Another Pair
Related Comparisons
HQH vs JPM: Head-to-Head Comparison
This page compares Abrdn Healthcare Investors (HQH) and JPMorgan Chase & Co. (JPM) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.